Hims & Hers (NYSE: HIMS) Crashes 11.98% on Q1 Miss and Weak Forward Guidance
Hims & Hers shares plummeted Tuesday after the telehealth provider reported a quarterly net loss and underwhelming earnings outlook.
Hims & Hers Health Inc. (NYSE: HIMS) is a company in the Health Care sector, listed on the NYSE. This page collects all Alpha Stocks Insight coverage of HIMS: earnings reports, analyst actions, and company news, updated as new articles are published. 4 articles since April 24, 2026.
Telehealth company plans convertible senior notes offering to fund international growth and accelerate AI-driven platform capabilities.
Hims & Hers shares plummeted Tuesday after the telehealth provider reported a quarterly net loss and underwhelming earnings outlook.
Hims & Hers Health gained on Monday amid strategic moves into AI-driven care and GLP-1 medications. Analysts remain broadly constructive despite a wide 52-week range.
HIMS gains 8.56% after JPMorgan initiation; GLP-1 expansion and Lilly partnership signal inflection point.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.